Could inhibiting B cells, rather than depleting them, offer a new approach to treating IgG4-related disease? In this interview from EULAR 2026, Dr Emanuel Della Torre discusses the unmet needs in IgG4-RD, the unique mechanism of the investigational therapy obexelimab, and key findings from the phase 3 INDIGO trial.

Hepatitis E virus (HEV) remains a major global cause of acute viral hepatitis, posing particular risks to pregnant women, immunocompromised individuals and patients with chronic liver disease. In this interview, Prof. Premashis Kar discusses the immunogenicity and safety findings from a phase 3 study of a recombinant HEV vaccine presented at EASL 2026, and explores how expanded vaccination strategies could help reduce the clinical and public health burden of HEV.

Polymyalgia rheumatica (PMR) is an inflammatory condition that is typically managed with glucocorticoids, but long-term treatment can be associated with significant adverse effects, underscoring the need for steroid-sparing therapies. The phase 3 REPLENISH trial investigated the efficacy and safety of secukinumab, an IL-17A inhibitor, in patients with PMR. In this interview, conducted at EULAR 2026, Dr Christian Dejaco (Hospital of Brunico, Brunico, Italy) discusses the rationale for targeting IL-17A, reviews the trial’s key findings, and considers their potential implications for clinical practice.

Idiopathic inflammatory myopathy (IIM) is a rare autoimmune disease associated with significant morbidity and limited treatment options, highlighting the need for novel therapeutic approaches. The ALKIVIA and ALKIVIA+ trials investigated efgartigimod, a neonatal Fc receptor (FcRn) antagonist, in adults with active IIM. In this interview, conducted at EULAR 2026, Dr Hector Chinoy (Salford Royal Hospital, Salford, UK) discusses the rationale for targeting FcRn, reviews the efficacy and safety findings from the studies, and considers their potential implications for the future management of IIM.

Overweight and obesity are common comorbidities in psoriatic arthritis (PsA) and can negatively affect disease activity and treatment response. The phase 3b TOGETHER-PsA trial evaluated the concomitant use of ixekizumab and tirzepatide in adults with PsA and overweight or obesity. In this interview, conducted at EULAR 2026, Dr Laura Coates (University of Oxford, Oxford, UK) discusses the rationale for this combination approach, highlights the study’s key findings, and considers their potential implications for the future management of PsA.

EASL Congress 2026 has concluded after four days of scientific exchange, collaboration and innovation, bringing together the global liver health community in Barcelona, Spain, and online. With more than 8,500 attendees from 120 countries and 2,278 scientific abstracts, this year's congress once again reinforced its position as a world leading meetings in hepatology.

POSITANO is a randomized, double-blind phase 2b trial investigating CAM2029 in patients with symptomatic polycystic liver disease (PLD). In this interview, Prof. Joost PH Drenth highlights the burden of PLD on patients, the unmet needs in its treatment, and explores the aims, design and findings of the phase 2b study, and the next steps in the development of CAM2029.

Acute-on-chronic liver failure (ACLF) is a severe and often life-threatening syndrome in patients with chronic liver disease, characterised by acute decompensation and a high risk of multi-organ failure. Yet differences in its definition across regions have hindered research and clinical progress. Ahead of EASL 2026, the Global ACLF Consensus Meeting brought international experts together to work toward a unified definition. In this interview, EASL Secretary General Prof. Debbie Shawcross discusses the challenges, key outcomes of the meeting, and the path toward global standardization of ACLF care and research.

Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your work, and what building that bench can mean for your career, and the life you build alongside it.